Heligan Group has reported a 26% year-on-year fall in UK healthcare M&A volumes for the first quarter of 2026, as tighter financing conditions and geopolitical uncertainty lengthen deal timelines.
The corporate finance group recorded 53 UK healthcare deals in Q1 2026, down from 72 in Q1 2025. The decline reflects a more cautious transaction environment, with investors applying greater scrutiny to valuations, borrowing costs, operating resilience, staffing exposure, and dependence on public-sector funding.
Despite the weaker headline number, activity remained visible across pharmaceuticals, life sciences, and medical devices. Heligan said the health and social care sector accounted for 57% of deals during the quarter, with consolidation continuing in fragmented and defensive subsectors including residential care, nurseries, complex care, pharmacies, and healthcare services.
Strategic buyers accounted for 81% of transactions, broadly in line with the 83% recorded in 2025. The pattern points to continuing emphasis on scale, pipeline expansion, and platform development, while private equity remained active in medical devices and pharmaceuticals despite slower execution.
The report identified several notable transactions, including GSK’s £1.7bn acquisition of RAPT Therapeutics, Smith & Nephew’s £450m acquisition of Integrity Orthopaedics, and Sovereign Capital Partners’ acquisition of Apollo Homecare. Cross-border activity also remained balanced, with 23% of deals inbound and 20% outbound. UK buyers continued to look towards the US, while also showing interest in France, Germany, and Belgium.
Healthcare is not immune from the wider dealmaking slowdown, but investor appetite has not disappeared. Capital is becoming more selective, with buyers looking for assets that can defend margins, integrate efficiently, and provide exposure to structural demand rather than discretionary growth alone.
That selectivity is particularly relevant to pharmaceutical manufacturing, medical devices, and life sciences supply chains. These sectors carry high regulatory barriers, long development cycles, demanding quality systems, and significant capital requirements. A slower deal market can reduce speculative activity, but it can sharpen interest in assets with validated manufacturing capability, specialist know-how, differentiated technology, or established routes into regulated markets.
Operational capability now carries more weight in strategic healthcare investment. Angelini Pharma’s greener API production work shows how process efficiency, environmental performance, quality control, and reliable manufacturing are being tied more closely to long-term value in pharmaceutical supply chains.
Medical device companies face a similar test. Product innovation has to sit alongside regulatory documentation, supplier qualification, materials traceability, and manufacturing repeatability. Assets with strong engineering capability, defensible customer relationships, and routes into international regulated markets can still draw interest when general M&A volumes soften.
Higher borrowing costs are changing the mechanics of that market. Reduced leverage makes buyers more cautious about assets that need heavy integration, operational turnaround, or major capital expenditure. Deal timelines lengthen as due diligence becomes more detailed, with investors paying closer attention to wage pressure, NHS exposure, reimbursement risk, input-cost inflation, and management depth.
Strategic buyers with strong balance sheets may still find opportunities. Lower competition can create room to acquire companies that strengthen a product pipeline, add manufacturing capacity, expand geographic reach, or bring specialist technologies in-house. In pharma, life sciences, and medtech, acquisitions are often used to reduce development risk, secure technical capability, or enter regulated markets faster than organic growth would allow.
The cross-border figures also show continuing international interest in UK healthcare assets. Domestic operating conditions remain difficult, but the UK’s research base, specialist services, medical technology ecosystem, and life sciences infrastructure still attract buyers. Outbound activity suggests UK companies are also looking for scale, market access, and technology overseas.
The Q1 fall therefore points to a slower and more disciplined market rather than a retreat from healthcare. Demand remains supported by demographics, chronic disease, technology adoption, and pressure to improve productivity across health systems. Companies able to demonstrate earnings quality, regulatory strength, operational control, and credible growth without relying on cheap finance are likely to remain the most resilient targets.
